FBRX · As filed with the SEC
Forte Biosciences balance sheet, by quarter
The statement as Forte Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Balance Sheets (Unaudited) · USD
| USD | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 | Q2 2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Assets | |||||
| Current assets: | |||||
| Cash and cash equivalents | 49,629,000 | 58,223,000 | 76,957,000 | 93,414,000 | 106,144,000 |
| Short-term investments | 148,831,000 | — | — | — | — |
| Prepaid expenses and other current assets | 4,643,000 | 6,887,000 | 3,632,000 | 1,998,000 | 1,472,000 |
| Total current assets | 203,103,000 | 65,110,000 | 80,589,000 | 95,412,000 | 107,616,000 |
| Property and equipment, net | 90,000 | 110,000 | 129,000 | 148,000 | 110,000 |
| Other assets | 2,550,000 | 2,003,000 | 2,061,000 | 1,529,000 | 57,000 |
| Total assets | 205,743,000 | 67,223,000 | 82,779,000 | 97,089,000 | 107,783,000 |
| Liabilities, convertible preferred stock and stockholders' equity | |||||
| Current liabilities: | |||||
| Accounts payable | 14,010,000 | 13,084,000 | 9,989,000 | 5,491,000 | 5,301,000 |
| Accrued liabilities | 6,279,000 | 10,563,000 | 10,762,000 | 7,501,000 | 3,869,000 |
| Total current liabilities | 20,289,000 | 23,647,000 | 20,751,000 | 12,992,000 | 9,170,000 |
| Income tax payable | — | — | 1,037,000 | — | — |
| Other liabilities | 1,660,000 | 1,476,000 | — | — | — |
| Total liabilities | 21,949,000 | 25,123,000 | 21,788,000 | — | — |
| Stockholders' equity: | |||||
| Common stock, $0.001 par value: 200,000,000 shares authorized as of June 30, 2026 (unaudited) and December 31, 2025; 20,482,400 and 12,948,308 shares issued and outstanding as of June 30, 2026 (unaudited) and December 31, 2025, respectively | 21,000 | 14,000 | 13,000 | 13,000 | 12,000 |
| Additional paid-in capital | 452,667,000 | 287,599,000 | 284,348,000 | 282,675,000 | 279,504,000 |
| Accumulated other comprehensive (loss) income | (54,000) | (4,000) | 3,000 | (6,000) | — |
| Accumulated deficit | (268,840,000) | (245,509,000) | (223,373,000) | (198,585,000) | (180,903,000) |
| Total stockholders’ equity | 183,794,000 | 42,100,000 | 60,991,000 | 84,097,000 | 98,613,000 |
| Total liabilities and stockholders' equity | 205,743,000 | 67,223,000 | 82,779,000 | 97,089,000 | 107,783,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.